Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Monovalent subvirion H5N1 influenza vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| 5 | EXPERIMENTAL | - |
| 6 | EXPERIMENTAL | - |
| 7 | ACTIVE_COMPARATOR | - |
| 8 | ACTIVE_COMPARATOR | - |
| 9 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Monovalent subvirion H5N1 influenza vaccine | BIOLOGICAL | 0.5 mL, IM, 2 injections, Formulation 1 |
| Physiological saline | BIOLOGICAL | 0.5 mL, IM, 2 injections |
Inclusion Criteria : * Healthy adult aged 18 to 40 years on the day of inclusion. * Provides signed informed consent prior to study procedures. * Able to attend all scheduled visits and comply with all trial procedures. * For a woman of child-bearing potential, avoid becoming pregnant (use of an ef...
Monovalent subvirion H5N1 influenza vaccine is an investigational vaccine being studied for the prevention of influenza, specifically targeting H5N1 avian influenza. It is currently in Phase 1 clinical development and is not yet approved for use.
Monovalent subvirion H5N1 influenza vaccine is being developed by Sanofi, a biopharmaceutical company listed on the stock exchange under the ticker SNY. The company is conducting clinical trials to evaluate the vaccine's safety and immunogenicity.
Monovalent subvirion H5N1 influenza vaccine is currently in Phase 1 clinical development. It is an investigational product and has not been approved by regulatory authorities. One Phase 1 trial has been completed to assess its safety and immune response.
Monovalent subvirion H5N1 influenza vaccine has been studied in one completed Phase 1 clinical trial, registered as NCT00664417. This trial evaluated different formulations of an intramuscular A/H5N1 inactivated, split virion influenza adjuvanted vaccine in 375 healthy adult volunteers in the United States.
Monovalent subvirion H5N1 influenza vaccine is being studied in formulations that include an adjuvant. The clinical trial NCT00664417 specifically tested different formulations of an A/H5N1 inactivated, split virion influenza vaccine with adjuvant, indicating that the vaccine is being developed as an adjuvanted formulation.